| Quarterly Financials | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
Revenue  | 195 | 165 | 250 | 285 | 208 | 271 | 252 | 330 | 228 | 320 | 261 | 439 | 219 | 263 | 288 | 341 | 272 |
| Expenses | 116 | 122 | 131 | 146 | 123 | 147 | 135 | 187 | 135 | 177 | 146 | 241 | 143 | 159 | 183 | 208 | 175 |
| EBITDA | 79 | 44 | 119 | 139 | 85 | 124 | 117 | 143 | 93 | 144 | 115 | 198 | 77 | 104 | 105 | 134 | 97 |
| Operating Profit % | 36 % | 24 % | 46 % | 47 % | 37 % | 44 % | 44 % | 41 % | 38 % | 43 % | 40 % | 44 % | 30 % | 36 % | 34 % | 36 % | 32 % |
| Depreciation | 14 | 13 | 14 | 14 | 13 | 13 | 14 | 14 | 13 | 13 | 13 | 15 | 18 | 18 | 19 | 20 | 18 |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 64 | 30 | 105 | 124 | 71 | 110 | 103 | 129 | 80 | 130 | 101 | 184 | 59 | 86 | 86 | 114 | 78 |
| Tax | 15 | 8 | 27 | 32 | 17 | 29 | 26 | 34 | 20 | 35 | 25 | 43 | 15 | 23 | 23 | 26 | 21 |
| Net Profit | 49 | 22 | 77 | 92 | 55 | 81 | 78 | 95 | 60 | 96 | 76 | 140 | 44 | 63 | 64 | 89 | 58 |
| EPS in ₹ | 4.71 | 2.10 | 7.40 | 8.75 | 5.21 | 7.74 | 7.41 | 9.08 | 5.70 | 9.15 | 7.26 | 13.42 | 4.21 | 6.03 | 6.08 | 8.46 | 5.52 |
Concord Biotech
Concord Biotech
1,401.60
+8.90
(0.64%)
Market Cap
14,663.01 Cr
PE Ratio
53.46
Volume
55,596.00
Day High - Low
1,426.80 - 1,393.00
52W High-Low
1,667.60 - 987.00
There are new updates from the company16 hrs ago
View
Key Fundamentals
Market Cap
14,663.01 Cr
EPS
24.78
PE Ratio
53.46
PB Ratio
7.23
Book Value
192.81
EBITDA
419.80
Dividend Yield
0.54 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
12.86
Debt to Equity
0.00
Analyst Rating and Forecast
- By Refinitiv from3 analysts
Actual
Company News
View All News
Concord Biotech Limited will close its trading window from October 1, 2026, until 48 hours after declaring Q2FY27 financial results, restricting insider trading.
Concord Biotech Ltd schedules board meeting for September 23, 2026, to consider a bonus equity share proposal. Trading window remains closed until September 26.
Concord Biotech to host analyst meet on Sep 23
Sep 17, 2026
Sep 17, 2026Concord Biotech Limited will hold a group meeting with investors and analysts on September 23, 2026, in Ahmedabad. The event is part of the JP Morgan Healthcare Trip.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,846.40 | #1 4,43,013.21 | 36.44 | #1 61,673.90 | 12.69 | #1 11,565 | 26.53 | 40.74 | |
9,529.50 | 2,52,978.28 | 86.51 | 11,067.00 | 13.95 | 2,568 | 65.50 | 63.87 | |
4,859.00 | 1,84,820.74 | 85.91 | 13,886.20 | 20.34 | 2,138 | 3.28 | 46.50 | |
1,218.50 | 1,22,609.61 | 26.32 | 27,657.90 | 17.64 | 5,026 | -34.90 | 66.57 | |
1,386.20 | 1,11,983.52 | 33.44 | 29,044.60 | 2.24 | 3,870 | -39.18 | 45.42 | |
2,011.60 | 1,08,597.55 | 99.70 | 6,867.80 | 22.01 | 890 | #1 123.93 | 64.04 | |
1,244.70 | 1,03,891.26 | 32.05 | 35,058.60 | 3.90 | 4,158 | -69.10 | 63.11 | |
2,494.00 | 1,03,001.20 | 48.73 | 14,636.40 | 14.85 | 1,938 | 29.13 | 55.24 | |
1,697.90 | 97,693.41 | 26.36 | 34,145.20 | 5.56 | 3,503 | 25.21 | 54.66 | |
2,074.00 | 94,830.03 | #1 16.99 | 29,038.90 | #1 26.75 | 5,356 | 16.00 | 35.30 |
Growth Rate
Revenue Growth
-11.03 %
Net Income Growth
-30.25 %
Cash Flow Change
9.14 %
ROE
-37.27 %
ROCE
-37.59 %
EBITDA Margin (Avg.)
-14.35 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 941 | 1,183 | 1,313 | 1,514 | 1,701 | 2,034 | 2,235 |
| Fixed Assets | 240 | 546 | 573 | 593 | 575 | 795 | 789 |
| Current Assets | 539 | 607 | 633 | 728 | 896 | 1,135 | 1,250 |
| Capital Work in Progress | 141 | 18 | 74 | 173 | 212 | 51 | 79 |
| Investments | 199 | 141 | 74 | 137 | 246 | 335 | 491 |
| Other Assets | 361 | 477 | 592 | 611 | 668 | 854 | 876 |
| Total Equity & Liabilities | 941 | 1,183 | 1,313 | 1,514 | 1,701 | 2,034 | 2,235 |
| Current Liabilities | 115 | 106 | 155 | 192 | 142 | 184 | 169 |
| Non Current Liabilities | 55 | 77 | 54 | 32 | 32 | 38 | 51 |
| Total Equity | 770 | 999 | 1,103 | 1,290 | 1,527 | 1,813 | 2,015 |
| Reserve & Surplus | 761 | 990 | 1,094 | 1,280 | 1,516 | 1,802 | 2,007 |
| Share Capital | 10 | 10 | 10 | 11 | 11 | 11 | 11 |
Cash Flow
| Cash Flow | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Net Cash Flow | -1 | 3 | -5 | 3 | 12 | -14 | 11 |
| Investing Activities | -114 | -195 | -112 | -158 | -155 | -160 | -143 |
| Operating Activities | 155 | 167 | 208 | 246 | 266 | 245 | 267 |
| Financing Activities | -43 | 31 | -100 | -85 | -99 | -99 | -113 |
Share Holding
| % Holding | Aug 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| Promoter | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % |
| FIIs | 0.00 % | 7.30 % | 0.00 % | 6.48 % | 7.11 % | 8.10 % | 8.33 % | 9.35 % | 9.11 % | 8.03 % | 7.58 % | 7.80 % | 7.52 % |
| DIIs | 4.89 % | 8.18 % | 8.13 % | 8.46 % | 10.40 % | 9.89 % | 9.66 % | 9.16 % | 8.87 % | 9.55 % | 9.58 % | 9.22 % | 9.36 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 13.33 % | 6.78 % | 6.76 % | 7.08 % | 7.64 % | 7.33 % | 7.33 % | 6.94 % | 7.43 % | 7.77 % | 8.11 % | 8.09 % | 8.23 % |
| Others | 37.69 % | 33.66 % | 41.03 % | 33.90 % | 30.76 % | 30.61 % | 30.59 % | 30.47 % | 30.51 % | 30.56 % | 30.64 % | 30.81 % | 30.81 % |
| No of Share Holders | 3,77,572 | 1,00,927 | 87,486 | 83,296 | 80,737 | 84,298 | 82,004 | 81,219 | 82,045 | 82,650 | 81,815 | 82,249 | 83,325 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.83 | 8.75 | 10.7 | 7.55 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.45 | 0.52 | 1.05 | 0.54 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 22 Jun 2024 |  Dividend | ₹ 8.75 /share | 21 Jun 2024 | 1,460.10 | 1,559.25 |
| 29 Jun 2024 |  Annual General Meeting | NA | 29 Jun 2024 | 1,460.10 | 1,549.05 |
| 11 Nov 2024 |  Quarterly Result Announcement | NA | 11 Nov 2024 | 1,812.25 | 1,850.00 |
| 13 Feb 2025 | Quarterly Result Announcement | NA | 13 Feb 2025 | 2,125.70 | 2,119.00 |
| 29 May 2025 | Quarterly Result Announcement | NA | 29 May 2025 | 1,532.10 | 1,635.70 |
| 08 Aug 2025 | Quarterly Result Announcement | NA | 08 Aug 2025 | 1,739.70 | 1,633.10 |
| 03 Sept 2025 | Dividend | ₹ 10.70 /share | 03 Sept 2025 | 1,635.70 | 1,691.15 |
| 09 Sept 2025 | Annual General Meeting | NA | 09 Sept 2025 | 1,648.30 | 1,610.20 |
| 13 Nov 2025 | Quarterly Result Announcement | NA | 13 Nov 2025 | 1,394.90 | 1,462.85 |
| 11 Feb 2026 | Quarterly Result Announcement | NA | 11 Feb 2026 | 1,168.20 | 1,283.50 |
| 29 May 2026 | Quarterly Result Announcement | NA | 29 May 2026 | 1,153.30 | 1,099.40 |
| 24 Jul 2026 | Dividend | ₹ 7.55 /share | 24 Jul 2026 | 1,099.40 | 1,268.50 |
| 31 Jul 2026 | Annual General Meeting | NA | 31 Jul 2026 | 1,284.00 | 1,333.20 |
| 31 Jul 2026 | Quarterly Result Announcement | NA | 31 Jul 2026 | 1,256.40 | 1,333.20 |
Announcements
Closure of Trading Window16 hrs ago
16 hrs agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication3 days ago
3 days agoShareholder Meeting / Postal Ballot-Notice of Postal Ballot4 days ago
4 days agoBoard Meeting Outcome for The Board Of Director At Its Meeting Held Today I.E. Wednesday September 23 2026 Has Inter-Alia Considered And Approved Issuance Of Bonus Shares & Increase In The Authorised Share Capital Of The Company.5 days ago
5 days agoBoard Meeting Intimation for Meeting To Be Held On Wednesday September 23 2026 Pursuant To Regulation 29 Of The SEBI (LODR) Regulations 2015 Inter-Alia To Consider The Proposal For Declaration Of Bonus Equity Shares To The Existing Equity Shareholders Of 9 days ago
9 days agoIntimation Of Outcome Of U.S. Food And Drug Administration (USFDA) Inspection At Unit II - Valthera Formulation Facility Of The CompanySep 18, 2026
Sep 18, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 17, 2026
Sep 17, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 21, 2026
Aug 21, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 07, 2026
Aug 07, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 03, 2026
Aug 03, 2026Announcement under Regulation 30 (LODR)-Investor PresentationAug 01, 2026
Aug 01, 2026Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 01, 2026
Aug 01, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2026
Aug 01, 2026Shareholder Meeting / Postal Ballot-Outcome of AGMJul 31, 2026
Jul 31, 2026Unaudited Standalone And Consolidated Financial Results For The First Quarter Ended On June 30 2026Jul 31, 2026
Jul 31, 2026Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. Friday July 31 2026 - Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 31, 2026
Jul 31, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 28, 2026
Jul 28, 2026Board Meeting Intimation for Meeting To Be Held On Friday July 31 2026Jul 28, 2026
Jul 28, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 08, 2026
Jul 08, 2026Intimation Of Record Date And Book Closure DateJul 07, 2026
Jul 07, 2026Business Responsibility and Sustainability Reporting (BRSR)Jul 07, 2026
Jul 07, 2026Reg. 34 (1) Annual Report.Jul 07, 2026
Jul 07, 2026Notice Of 41St Annual General Meeting Of The Company For The Financial Year 2025-26Jul 07, 2026
Jul 07, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 06, 2026
Jul 06, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 06, 2026
Jul 06, 2026Closure of Trading WindowJun 27, 2026
Jun 27, 2026Completion Of Inspection By The Pharmacy And Poisons Board (PPB) From Kenya And The National Drug Authority (NDA) From Uganda At Unit-II Formulation FacilityJun 25, 2026
Jun 25, 2026Announcement under Regulation 30 (LODR)-AcquisitionJun 20, 2026
Jun 20, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 19, 2026
Jun 19, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 13, 2026
Jun 13, 2026Completion Of ANVISA Inspection Conducted By The Brazilian Health Regulatory Agency At The Limbasi API Manufacturing FacilityJun 12, 2026
Jun 12, 2026Concord Biotech Secures Abbreviated New Drug Application (ANDA) Approval For Tofacitinib Tablets 5 Mg And 10 MgJun 10, 2026
Jun 10, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 05, 2026
Jun 05, 2026Concord Biotech Secures Abbreviated New Drug Application (ANDA) Approval For Mycophenolate Mofetil For Oral Suspension USP 200 Mg/MlJun 02, 2026
Jun 02, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJun 01, 2026
Jun 01, 2026Announcement under Regulation 30 (LODR)-Investor PresentationMay 30, 2026
May 30, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 30, 2026
May 30, 2026Corporate Action-Board approves DividendMay 29, 2026
May 29, 2026Announcement under Regulation 30 (LODR)-Change in ManagementMay 29, 2026
May 29, 2026Announcement under Regulation 30 (LODR)-Change in ManagementMay 29, 2026
May 29, 2026Audited Standalone And Consolidated Financial Results For The Fourth Quarter And Financial Year Ended On March 31 2026May 29, 2026
May 29, 2026Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. Friday May 29 2026May 29, 2026
May 29, 2026Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 26, 2026
May 26, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 26, 2026
May 26, 2026Board Meeting Intimation for Meeting To Be Held On Friday May 29 2026 Pursuant To Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 23, 2026
May 23, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 08, 2026
Apr 08, 2026Announcement under Regulation 30 (LODR)-Updates on AcquisitionApr 02, 2026
Apr 02, 2026Closure of Trading WindowMar 27, 2026
Mar 27, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 26, 2026
Feb 26, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2026
Feb 20, 2026Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 41.26
ATR(14)
Volatile 57.38
STOCH(9,6)
Neutral 48.05
STOCH RSI(14)
Oversold 8.81
MACD(12,26)
Bearish -9.38
ADX(14)
Weak Trend 18.33
UO(9)
Bearish 43.81
ROC(12)
Downtrend And Accelerating -4.90
WillR(14)
Oversold -95.77
About Concord Biotech
Concord Biotech Limited is an India-based biopharma company that develops and manufactures fermentation-based APIs and formulations. It focuses on immunosuppressants, oncology, anti-infectives, nephrology, and critical care. The company operates three manufacturing facilities in Gujarat, India, with a total annual installed fermentation capacity of 1,250 m3 for APIs. Concord Biotech supplies...more
Listing Date
18 Aug, 2023(3 Years, 1 Month, 11 Days)
Chairperson NameSUDHIR JAIRAM VAID
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
